Pharmaceutical Technology
11.10. 2024
XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. Under the agreement, Ailux Biologics grants Janssen and its affiliates a non-exclusive license to leverage its XtalFold™ platform for the discovery and engineering of biologics. XtalFold™ is a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases. The agreement was facilitated by Johnson & Johnson Innovation.
PR News
07.11.2024
XtalPi has announced a strategic partnership with Indonesia's powerhouse, led by one of its prominent business pillar Sinar Mas Multiartha. This landmark collaboration is set to transform the future of artificial intelligence (AI) and robotics across the Asia-Pacific region. By establishing an ambitious joint venture, the alliance will integrate XtalPi's cutting-edge AI and robotics research capabilities with Sinar Mas Group's extensive industry reach, setting the stage for a commercial and technological revolution.
Disclaimer
Investment Involves risk. Past performance does not represent future performance. Investor should read the product’s Prospectus for details and risk factors before making investment decision. The contents of this website is prepared and maintained by Mirae Asset Capital (China) Limited. This material has not been reviewed by the Securities and Futures Commission.
Dec 13, 2024
